Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986419 Pharmacokinetics Interaction Study with Probe Substrates
NCT05932277Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986419 in amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration and 1 more. Started Jun 2023; status: completed.
02
Drugs
BMS-986419
03
Conditions
amyotrophic lateral sclerosis (ALS)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05932277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932277.